Speciality Medicines logo

Speciality Medicines financials and balance sheet

BSE: 544738Pharmaceuticals & BiotechnologySmall Cap

Last close ₹141.80down ₹7.20 (4.83%)

Share price at the BSE close on 23 Oct 2026. Previous close ₹149.00.

Range of traded prices from listing on 30 Mar 2026 to 23 Oct 2026
₹121.10Low, 6 Apr 2026₹381.20High, 29 Apr 2026
Market cap
₹125 Cr2,392nd largest listed
P/E
9.6
P/B
1.7
Dividend yield
Nonesince listing in Mar 2026
ROE
18.3%
Debt to equity
0.09
Volume, BSE
16,000

1 year at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Speciality Medicines annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue75
  2. Materials and goods−54
  3. Employee costs−1.7
  4. Other expenses−5.7
  5. Operating profit14
  6. Depreciation−0.2
  7. Other income+0.8
  8. Finance costs−1.3
  9. Profit before tax13
  10. Tax0.0
  11. Net profit13

What the company owns

  • Inventory₹28 Cr
  • Receivables₹27 Cr
  • Cash and bank₹25 Cr
  • Plant, investments and other assets₹16 Cr

What pays for it: net worth and liabilities

  • Net worth₹71 Cr
  • Owed to suppliers₹12 Cr
  • Borrowings₹7 Cr
  • Other liabilities₹5 Cr

Profit and loss

Standalone, ₹ crore, years to March.Speciality Medicines half-yearly results

₹ croreMar 2026Filed 28 May
Revenue from operations75.3
61.6
Materials and goods bought54.1
Employee costs1.7
Other expenses5.7
Operating profit before depreciation13.7
Operating margin18.2%
Materials, % of revenue71.9%
Employee costs, % of revenue2.3%
Other expenses, % of revenue7.6%
Depreciation and amortisation0.2
Operating profit after depreciation13.5
Other income0.8
Finance costs1.3
Profit before tax13.0
Tax0.0
Net profit13.0
Net margin17.3%

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2026Filed 28 May
71.2
Share capital8.8
Reserves62.4
6.6
18.8
5.2
Total assets95.2
6.3
89.0
Net debt−17.9
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2026Filed 28 May
−1.3
−15.8
Receivables−16.9
Inventories−10.9
Payables10.9
Other working capital1.1
Capital spending0.0
Free cash flow−1.3
Cash from investing−2.8
27.8
Dividends paid0.0
Shares issued29.1
Net change in cash23.7
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2026Filed 28 May
Earnings per share₹20.11
Diluted earnings per share₹20.11
Book value per share₹81.03
Shareholder yield−26.3%
Market cap at the year end (₹ crore)111

Ratios

Standalone, years to March.Speciality Medicines PE ratio and valuation

RatioMar 2026Filed 28 May
Return on equity18.3%
Return on capital employed17.4%
Cash conversion−9.8%
Interest cover10.2
Debt to equity0.09
Receivable days128
Inventory days191
Payable days80
Cash conversion cycle, days239
Working capital days229
Asset turnover0.79
Assets per rupee of net worth1.34
Sales per rupee of plant43.95
Capital spending to depreciation0.05

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
13.7%
Cash from operations against operating profit
−9.4%

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations−1.3
Cash from investing−2.8
Cash from financing27.8
Capital spending0.0
Dividends paid0.0
Shares issued for cash29.1
Borrowings raised2.4
Borrowings repaid0.8

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2026
Effective tax ratePublished threshold 17.16 per cent−0.11
Tax charged less tax paid, % of profitOur threshold 10 percentage points−0.11
A threshold marked as ours has no published figure; it is the line we read the check against.